
Tampax is owned by Procter & Gamble (NYSE: PG), a publicly traded American consumer goods corporation headquartered in Cincinnati, Ohio. P&G acquired Tampax in 1997 through its approximately $1.85 billion purchase of Tambrands, the brand's then-parent company. Tampax operates as a wholly-owned brand within P&G's Baby, Feminine & Family Care segment and is sold in over 100 countries worldwide.
Parent Company
Acquired
1997
Status
Publicly Traded
Headquarters
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Tampax | Procter & Gamble Company | Wholly owned |
The origins of Tampax date to 1929, when Earle Haas, a physician in Denver, Colorado, developed the concept for an internal menstrual protection device with a removable cardboard applicator. Haas was motivated by a desire to create a more discreet and convenient alternative to the bulky external pads available at the time. He patented his invention in 1931, calling it a "catamenial device," using the medical term for menstruation.
Haas attempted to sell his patent to Kimberly-Clark, the manufacturer of Kotex pads, but the company declined. In 1933, he sold the patent to Gertrude Tendrich, a Denver businesswoman, for approximately $32,000. Tendrich founded the Tampax Sales Corporation in 1934 and began manufacturing tampons commercially. The brand name "Tampax" combined "tampon" and "vaginal pack."
The early years were difficult. Internal menstrual protection was a radical concept that faced significant social resistance. Many women were unfamiliar with the idea, and concerns about safety and appropriateness were widespread. Tendrich and her team invested heavily in education, using direct mail campaigns, doctor outreach, and nurse partnerships to build credibility.
World War II changed the trajectory. As millions of American women entered factory and military roles, the practical advantages of tampons over bulky pads became obvious. Women working in physically demanding jobs found tampons far more convenient. By the end of the war, Tampax had established itself as a mainstream consumer product.
Through the 1950s and 1960s, Tampax expanded its product line with multiple absorbency levels (Regular, Super, Super Plus) and improved applicator designs. The company invested heavily in advertising, becoming one of the first feminine hygiene brands to advertise openly in mainstream magazines and on television.
In the 1970s and 1980s, Tampax faced its most serious crisis. Toxic shock syndrome (TSS), a rare but potentially fatal bacterial infection, was linked to super-absorbent tampon use. The FDA required warning labels on all tampon packaging. Tampax responded by reformulating its products, removing certain super-absorbent materials, and launching consumer education campaigns about proper tampon use. The TSS crisis affected the entire tampon industry but ultimately led to safer products and better consumer information.
Tambrands, the corporate parent of Tampax, was acquired by Procter & Gamble in 1997 for approximately $1.85 billion. The acquisition brought Tampax into P&G's portfolio alongside Always, creating a comprehensive feminine care business covering both internal and external menstrual protection. Under P&G's ownership, Tampax has introduced several product innovations, including the Tampax Pearl line with a redesigned plastic applicator, Tampax Compak for compact portability, Tampax Radiant with improved leak protection, and Tampax Pure Cotton, which uses 100% organic cotton.
In July 2024, researchers at Columbia University Mailman School of Public Health and UC Berkeley published the first study to measure metals in tampons. The study detected measurable concentrations of 16 metals, including lead, cadmium, and arsenic, in tampons from 14 brands. This study and subsequent regulatory scrutiny have created new challenges for the brand.
Procter & Gamble delivered mixed financial results in fiscal 2026, reflecting both the strength of its business model and challenges in the current consumer environment. In Q2 2026, P&G reported adjusted earnings per share of $1.88, exceeding Wall Street expectations of $1.86, while revenue of $22.21 billion fell slightly short of analyst expectations of $22.28 billion. The company's ability to beat earnings estimates despite revenue challenges demonstrates the effectiveness of its productivity initiatives and cost management strategies.
Financial Performance Overview shows P&G's resilience in a challenging market. The company revised its fiscal 2026 earnings outlook to 1% to 6% net earnings per share growth, down from the previous forecast of 3% to 9%, citing higher restructuring charges. Despite this adjustment, P&G maintained its sales growth guidance, reflecting confidence in its business fundamentals and strategic positioning. CFO Andre Schulten noted that "We've now completed what we fully expect will be the softest quarter of the fiscal year," indicating anticipation of improved performance in the second half.
Volume Performance revealed significant challenges across key categories, with overall volume falling 1% as three out of five product categories reported shrinking volume. This decline reflects broader consumer behavior patterns as inflation-weary consumers hunt for deals and reduce discretionary spending, particularly in P&G's largest market, the United States. Despite these challenges, Schulten emphasized that "People have not stopped washing their hair, they still buy diapers, they do their laundry — albeit at a little bit slower pace, so the market growth has certainly slowed over the last 18 to 24 months."
Segment Performance showed divergent trends across P&G's business portfolio. The baby, feminine and family care segment experienced the steepest decline with volume falling 5% in Q2 2026, facing tough comparisons with the year-ago period when retailers and consumers stocked up ahead of expected port strikes. The grooming business, which includes Gillette and Venus razors, reported a 2% volume drop, reflecting ongoing competitive pressures in the men's grooming market. The health-care segment saw volume fall 1%, including brands like Oral-B, Vicks, and Pepto-Bismol.
Bright Spots in Performance were primarily in the beauty segment, which was the only division to report volume growth, rising 3% fueled by stronger demand for hair-care products. The fabric and home-care business, which includes brands like Febreze and Tide, reported unchanged volume, demonstrating stability in P&G's largest business segment by revenue. These performance variations highlight the importance of P&G's diversified portfolio strategy in navigating market challenges.
Q1 2026 Results demonstrated stronger performance compared to Q2, with net sales of $22.4 billion, up 3% versus the prior year, and organic sales increasing 2%. The company achieved diluted EPS of $1.95 (up 21% YoY) and core EPS of $1.99 (up 3% YoY), reflecting strong operational execution. Operating cash flow was $5.4 billion, and the company returned $3.8 billion to shareholders through dividend payments and share repurchases, demonstrating P&G's commitment to shareholder returns.
Consumer Market Dynamics continue to shape P&G's performance, with the company facing "softer consumer markets, aggressive competition, and a dynamic geopolitical landscape" according to CFO Schulten. These challenges reflect broader economic pressures affecting consumer spending patterns and competitive intensity in key categories. However, P&G expects stronger results in the second half of the fiscal year, fueled by upcoming innovation and improved market conditions.
Innovation and Demand Creation remain central to P&G's strategy for driving growth. The company is increasing investment in innovation and demand creation to improve value for consumers and drive category growth. This focus on innovation is particularly important in the beauty segment, where new product development and marketing initiatives have helped drive volume growth despite overall market challenges.
Q3 2026 Results showed a significant acceleration in performance. P&G reported net sales of $21.24 billion, up 7% versus the prior year, beating Wall Street expectations of $20.5 billion. Organic sales increased 3%, driven by a 2% increase in volume — the first time in a year that P&G reported growing volume across the company. Core EPS of $1.59 beat estimates of $1.56, up 3% YoY. Diluted EPS was $1.63, up 6%, boosted by a gain from the dissolution of the Glad joint venture business. CEO Shailesh Jejurikar stated: "We delivered a solid acceleration in top-line results in our fiscal third quarter, with broad-based growth across product categories and regions." All five segments posted net sales growth: Beauty +11% ($3.87B), Fabric & Home Care +7% ($7.4B), Baby/Feminine/Family Care +6% ($5.06B), Health Care +7% ($3.07B), and Grooming +7% ($1.61B). The company returned $3.2 billion to shareholders via $2.5 billion in dividends and over $600 million in share repurchases. However, P&G warned about uncertainty from the Iran war's effects on input costs and consumer spending, projecting approximately $400 million in after-tax tariff costs and $150 million in commodity cost headwinds. If Brent crude stays around $100/barrel, P&G projects an annual after-tax headwind of $1 billion. The company will not provide a fiscal 2027 forecast until its July earnings report.
Leadership Transition Impact represents a significant element of P&G's current strategy. Shailesh Jejurikar's appointment as CEO effective January 1, 2026, brings fresh perspectives while maintaining continuity through Jon Moeller's transition to Executive Chairman. Jejurikar described his vision at the CAGNY Conference: leveraging P&G's strengths to "create the CPG company of the future."
Geographic Performance varied across P&G's global markets, with the United States facing particular challenges due to consumer behavior changes and competitive pressures. However, the company's global diversification provides stability, with different regions experiencing varying levels of economic pressure and consumer demand patterns.
Supply Chain and Operations have been optimized to support P&G's productivity initiatives and cost management strategies. The company's integrated supply chain encompasses suppliers, manufacturing partners, and retailers in complex networks ensuring product availability worldwide while maintaining operational efficiency.
Future Outlook remains cautiously optimistic, with P&G maintaining its fiscal year 2026 guidance for all-in sales growth of 1% to 5% and net EPS growth of 1% to 6% versus FY2025 diluted EPS of $6.51. Core EPS growth guidance is in-line to up 4% versus FY2025 core EPS of $6.83, equating to $6.83 to $7.09 per share. However, earnings are expected to trend toward the lower end of the range as cost headwinds persist and investments step up. The company faces approximately $400 million in after-tax tariff costs and $150 million in commodity cost headwinds. P&G will not provide a fiscal 2027 forecast until its July 2026 earnings report, citing uncertainty from the Iran war's impact on input costs and consumer spending.
Investor Confidence remained strong despite mixed results, with P&G shares rising more than 2% in morning trading following the Q2 earnings announcement. This positive market response reflects investor confidence in P&G's ability to navigate current challenges while positioning for future growth through strategic initiatives and operational excellence.
P&G's recent performance demonstrates the company's ability to maintain profitability and shareholder returns while navigating challenging market conditions. The combination of operational efficiency, brand strength, and strategic focus on innovation provides a solid foundation for continued success in the competitive consumer goods industry.
Tampax operates under Procter & Gamble's corporate sustainability framework. P&G has set science-based targets to reduce greenhouse gas emissions by 50% by 2030 and achieve net zero emissions by 2040. These corporate commitments apply to Tampax manufacturing facilities in the United States, Mexico, China, and Poland.
The brand has introduced the Tampax Pure Cotton line, which uses 100% organic cotton certified to USDA Organic standards. However, the broader Tampax product range uses conventional cotton and rayon, and the brand does not hold independent certifications from organizations such as Leaping Bunny or PETA for cruelty-free status. P&G does conduct animal testing on certain products where required by regulation, which has drawn criticism from animal welfare organizations.
Tampax faces ongoing environmental criticism over the waste generated by disposable tampons and applicators. A single tampon with a plastic applicator can take hundreds of years to decompose. Environmental advocates have called for biodegradable applicators and reduced packaging. Tampax has introduced cardboard applicator options in some markets, but plastic applicators remain the primary format for its Pearl and Radiant lines.
P&G publishes an annual Environmental, Social, and Governance (ESG) report that covers Tampax manufacturing operations. The company reports on water usage, waste reduction, and energy efficiency at its feminine care production facilities. However, specific data for Tampax operations is not broken out separately from P&G's broader Baby, Feminine & Family Care segment.
The brand has also faced criticism for its historical marketing practices, including the use of blue liquid in advertisements rather than realistic depictions of menstruation. This practice, common across the feminine hygiene industry through the 1980s and 1990s, has been criticized for contributing to menstrual stigma. Tampax and other brands have begun using more realistic representations in recent years.
Tampax has faced several significant controversies throughout its history, primarily related to product safety, chemical concerns, and marketing practices.
Toxic Shock Syndrome (TSS) Crisis (1980s): The most serious safety crisis in Tampax's history occurred in the early 1980s, when toxic shock syndrome was linked to super-absorbent tampon use. TSS is a rare but potentially fatal bacterial infection caused by Staphylococcus aureus toxins. The crisis peaked in 1980, when over 800 cases were reported in the United States, with a significant majority associated with tampon use. The FDA required warning labels on all tampon packaging, and Tampax reformulated its products to remove certain super-absorbent materials. Warning labels about TSS remain on tampon packaging today, and incidence has declined significantly since the 1980s.
Heavy Metals Study (2024): In July 2024, researchers at Columbia University Mailman School of Public Health and UC Berkeley published the first study to measure metals in tampons. The study, published in Environment International, detected measurable concentrations of 16 metals in tampons from 14 brands, including lead (geometric mean of 120 ng/g), cadmium, and arsenic. Lead concentrations were higher in non-organic tampons, while arsenic was higher in organic tampons. The study noted that it remains unclear whether these metals can leach out of tampons and be absorbed by the body. The findings generated significant media coverage and consumer concern.
Texas Attorney General Investigation (July 2026): In July 2026, Texas Attorney General Ken Paxton launched an industry-wide investigation into several feminine care brands, including Tampax, over concerns about potentially harmful chemicals in their products. The investigation issued Civil Investigative Demands to Tampax and other brands, examining whether companies misled consumers about the safety and chemical composition of their products. The investigation cited the 2024 Columbia University study and noted that public health authorities have stated there is no known safe level of lead exposure. The investigation is ongoing as of August 2026.
Norway Environmental Information Request (2025): In 2025, Norwegian media outlet VG requested detailed information from Procter & Gamble Norway AS about heavy metal content in Tampax products sold in Norway, under Norway's environmental information and product control laws. P&G provided some testing data but did not release complete laboratory reports or raw data for all Tampax variants. The case was appealed to Norway's Environmental Complaints Board. P&G stated that its testing showed Tampax products do not contain heavy metals above established safety thresholds.
Marketing and Period Stigma Criticism: Tampax has been criticized for decades of marketing practices that avoided showing actual blood or realistic depictions of menstruation. The brand's use of blue liquid in advertisements through the 1980s and 1990s reflected broader cultural discomfort with menstruation. Critics argue this contributed to menstrual stigma and made it difficult for consumers to discuss menstrual health openly.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Essity | USA | 1964 | Value | United States | Womens | |
| Kenvue | United States | 1971 | Mass market | Global | Womens | |
| Procter Gamble | USA | 1983 | Mass market | Global | Womens |
Beauty Personal CareOwned by Essity AB
American feminine hygiene brand producing panty liners and feminine care products, now owned by Essity, a Swedish global hygiene and health company.
Healthcare PharmaceuticalsOwned by Kenvue
Feminine hygiene brand of menstrual pads owned by Kenvue globally and Energizer Holdings in North America. Kenvue is being acquired by Kimberly-Clark in a deal expected to close in 2026.
Beauty Personal CareOwned by Procter & Gamble Company
Procter & Gamble's feminine hygiene brand launched in 1983, holding approximately 27% global market share in menstrual pads and sold in more than 100 countries.
Market Positioning: Tampax competes with 3 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by Procter & Gamble Company, giving you alternative choices that support different corporate structures.
Beauty Personal CareOwned by Evyap
Mass-market soap and personal care brand owned by Evyap, sold in over 100 countries with strong positions in Eastern Europe and the Middle East.
Fax is privately owned, unlike Tampax which is under a publicly traded parent company.
Beauty Personal CareOwned by Evyap
Men's personal care and grooming brand owned by Evyap, a privately held Turkish personal care company founded in 1927. Gibbs offers shaving products, deodorants, and grooming items primarily in European, Middle Eastern, and Central Asian markets.
Gibbs is privately owned, unlike Tampax which is under a publicly traded parent company.
Beauty Personal CareOwned by Great Clips, Inc.
Value hair salon franchise brand owned by Great Clips, Inc. and operated through more than 4,400 franchisee-owned salons.
Great Clips is privately owned, unlike Tampax which is under a publicly traded parent company.
Beauty Personal CareOwned by Evyap
Turkish brand of men's grooming and shaving products manufactured and marketed by Evyap, known for affordable quality shaving soaps.
Arko is privately owned, unlike Tampax which is under a publicly traded parent company.
Beauty Personal CareOwned by Nexus Capital Management
American direct-to-consumer razor and grooming brand known for its subscription model and viral marketing.
Dollar Shave Club is privately owned, unlike Tampax which is under a publicly traded parent company.
Beauty Personal CareOwned by Evyap
Turkish beauty and bath soap brand manufactured by Evyap. Sold in over 100 countries. Known for natural ingredients including olive oil, shea butter, and coconut. Market leader in Eastern Europe and Central Asia.
Duru is privately owned, unlike Tampax which is under a publicly traded parent company.
Discover popular brands and companies in the Beauty & Personal Care category and related searches from other users.

Italian luxury fragrance and grooming brand founded in Parma in 1916, owned by LVMH since 2001. Known for its signature Colonia fragrance and a full range of home and lifestyle products made in Italy.

Turkish antibacterial soap and personal hygiene brand owned by Evyap, one of Turkey's largest consumer goods manufacturers. Activex uses silver ion technology and is sold primarily in Turkey and Middle Eastern markets.

Procter & Gamble's feminine hygiene brand launched in 1983, holding approximately 27% global market share in menstrual pads and sold in more than 100 countries.